These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
336 related articles for article (PubMed ID: 29906591)
1. Toxicity of nifurtimox as second-line treatment after benznidazole intolerance in patients with chronic Chagas disease: when available options fail. Crespillo-Andújar C; Chamorro-Tojeiro S; Norman F; Monge-Maillo B; López-Vélez R; Pérez-Molina JA Clin Microbiol Infect; 2018 Dec; 24(12):1344.e1-1344.e4. PubMed ID: 29906591 [TBL] [Abstract][Full Text] [Related]
2. Nifurtimox therapy for Chagas disease does not cause hypersensitivity reactions in patients with such previous adverse reactions during benznidazole treatment. Pérez-Molina JA; Sojo-Dorado J; Norman F; Monge-Maillo B; Díaz-Menéndez M; Albajar-Viñas P; López-Vélez R Acta Trop; 2013 Aug; 127(2):101-4. PubMed ID: 23583863 [TBL] [Abstract][Full Text] [Related]
3. Comparison of the toxicity of two treatment schemes with benznidazole for chronic Chagas disease: a prospective cohort study in two Spanish referral centres. Crespillo-Andújar C; López-Vélez R; Trigo E; Norman F; Díaz-Menéndez M; Monge-Maillo B; Arsuaga M; Pérez-Molina JA Clin Microbiol Infect; 2020 Mar; 26(3):384.e1-384.e4. PubMed ID: 31740423 [TBL] [Abstract][Full Text] [Related]
4. Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection). Vallejo M; Reyes PP; Martinez Garcia M; Gonzalez Garay AG Cochrane Database Syst Rev; 2020 Dec; 12(12):CD004102. PubMed ID: 33305846 [TBL] [Abstract][Full Text] [Related]
5. Tolerance to nifurtimox and benznidazole in adult patients with chronic Chagas' disease. Jackson Y; Wyssa B; Chappuis F J Antimicrob Chemother; 2020 Mar; 75(3):690-696. PubMed ID: 31754690 [TBL] [Abstract][Full Text] [Related]
6. [Comparative controlled study on the use of benznidazole, nifurtimox and placebo, in the chronic form of Chagas' disease, in a field area with interrupted transmission. I. Preliminary evaluation]. Coura JR; de Abreu LL; Willcox HP; Petana W Rev Soc Bras Med Trop; 1997; 30(2):139-44. PubMed ID: 9148337 [TBL] [Abstract][Full Text] [Related]
7. Assessing antibody decline after chemotherapy of early chronic Chagas disease patients. Murphy N; Cardinal MV; Bhattacharyya T; Enriquez GF; Macchiaverna NP; Alvedro A; Freilij H; Martinez de Salazar P; Molina I; Mertens P; Gilleman Q; Gürtler RE; Miles MA Parasit Vectors; 2021 Oct; 14(1):543. PubMed ID: 34670602 [TBL] [Abstract][Full Text] [Related]
8. Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States. Forsyth CJ; Hernandez S; Olmedo W; Abuhamidah A; Traina MI; Sanchez DR; Soverow J; Meymandi SK Clin Infect Dis; 2016 Oct; 63(8):1056-1062. PubMed ID: 27432838 [TBL] [Abstract][Full Text] [Related]
9. Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial. Villar JC; Herrera VM; Pérez Carreño JG; Váquiro Herrera E; Castellanos Domínguez YZ; Vásquez SM; Cucunubá ZM; Prado NG; Hernández Y Trials; 2019 Jul; 20(1):431. PubMed ID: 31307503 [TBL] [Abstract][Full Text] [Related]
10. Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution. Fabbro DL; Streiger ML; Arias ED; Bizai ML; del Barco M; Amicone NA Rev Soc Bras Med Trop; 2007; 40(1):1-10. PubMed ID: 17486245 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of cytokine profile and HLA association in benznidazole related cutaneous reactions in patients with Chagas disease. Salvador F; Sánchez-Montalvá A; Martínez-Gallo M; Sala-Cunill A; Viñas L; García-Prat M; Aparicio G; Sao Avilés A; Artaza MÁ; Ferrer B; Molina I Clin Infect Dis; 2015 Dec; 61(11):1688-94. PubMed ID: 26265500 [TBL] [Abstract][Full Text] [Related]